

29 May 2018

**MARKET UPDATE:
GERMANY'S FIRST SPECIALIST MEDICAL CANNABIS CLINIC NOW FULLY OPERATIONAL**

The Directors of 1-Page Limited (ASX:1PG) (**Company**) are pleased to announce that the HAPA Medical Group (**HAPA**) that was opened on 1 March 2018 as Germany's first specialist medical cannabis clinic in Berlin is experiencing very strong patient bookings since its opening. This reflects the significant growth in registered patient numbers since full Federal legalization in Germany was put in place approximately 12 months ago. This is a key milestone for HAPA and cements its position as an early mover into the booming German medical cannabis market. Unlike other countries which have also legalized medicinal cannabis, in Germany in many cases the costs of medical cannabis products are reimbursed to the patient directly by medical insurance providers.

The Company has entered into a share sale agreement to acquire 100% of HAPA, subject to certain conditions (refer to ASX announcement dated 2 February 2018).

HAPA is an early mover in the German medicinal cannabis market and is focused on offering its own pharmaceutical GMP-grade THC & CBD product lines to patients through a network of HAPA owned medical cannabis clinics throughout Germany. HAPA also plans to extend this distribution to other general medical clinics and pharmacies throughout Germany in the coming months via partnering and distribution arrangements.

Furthermore, HAPA has identified sites and medical staff for several new specialist medicinal cannabis clinics expected to be opened in the second half of CY 2018 in Dortmund, Hamburg and Munich. These sites provide access to a population catchment area in excess of Australia's total population highlighting the significantly larger opportunity available in the German market.

Background on medicinal cannabis in Germany

Laws legalising the broad use of medicinal cannabis were passed in Germany in March 2017. With a population of 83 million people, Germany is estimated to have the potential to become the world's single largest medical cannabis market.

Under the German regulatory framework, German patients are required to register as a patient for the receipt of medicinal cannabis products and the growth in the number of registered patients is far exceeding initial industry forecasts.

In Germany, the health insurance industry heavily subsidises the cost of cannabis related medicines. This is a key driver accelerating patient uptake and key differentiator between the Australian and Canadian markets where there is limited to no health insurance subsidies available to patients seeking to use medicinal cannabis as an alternative to existing subsidised medicines, such as opiates.

Transaction Update

The Board of 1-Page are in active and ongoing discussions with the Australian Securities Exchange (ASX) in relation to the requirements for completing the acquisition of HAPA. Confirmation of these requirements is required ahead of being able to call a shareholder meeting to approve the transaction.

At the same time, the Company is exploring other listing alternatives in certain overseas markets where interest from investors is significant including but not limited to Germany, Canada and the United Kingdom. Should the Company seek to pursue an overseas listing it will take steps to de-list from ASX and expedite the completion of the acquisition and re-listing.

END